<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302131</url>
  </required_header>
  <id_info>
    <org_study_id>EU Pulmonic XT</org_study_id>
    <nct_id>NCT02302131</nct_id>
  </id_info>
  <brief_title>Pulmonic SAPIEN XT THV</brief_title>
  <acronym>Pulmonic XT</acronym>
  <official_title>Pulmonic SAPIEN XT™ THV A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Estimate, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, Observational Registry with Retrospective Enrollment and Prospective Follow-up.

      The aim of the registry is to document the feasibility and safety of implanting an Edwards
      SAPIEN XT transcatheter heart valve in the pulmonic position.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A malfunction or dysplasia of the pulmonary valve or the right ventricular outflow tract
      (RVOT) is one of the major components of the cardiac physiology in many congenital heart
      defects. Surgical correction of complex heart defects often includes some form of surgical
      repair or replacement of the native RVOT by biological valves such as homograft,
      bioprosthesis or Xenografts (i.e., Contegra conduits). Typical examples are tetralogy of
      Fallot (TOF) or double outlet right ventricle (DORV), pulmonary stenosis (PS), pulmonary
      atresia (PA), truncus arteriosus (TA), transposition of the great arteries (TGA) with PS
      (Rastelli's operation), absent pulmonary valve syndrome (Miller-Lev-Paul), Ross surgery for
      aortic valve disease and others. The repaired or replaced pulmonary valve however often
      becomes dysfunctional later on and many patients require surgical revisions of the RVOT with
      pulmonary valve replacement within 10 years of primary intervention.

      TPVI provides a less invasive alternative to surgery in patients with right
      ventricular-to-pulmonary artery (RV-PA) conduit dysfunction. Early results of percutaneous
      pulmonary valve implantation (PPVI) showed that it is a promising procedure compared to a
      conventional surgical intervention. Meanwhile, pre-stenting of the RVOT before PPVI is
      routinely performed, enabling PPVI in various anatomies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>right ventricular and pulmonary artery pressure</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>max flow velocity RVOT</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NYHA class</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>degree of pulmonary regurgitation</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>procedural success</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak gradient</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Oxygen consumption</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>anaerobic threshold</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>device function</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>structural valve Deterioration including stent fracture</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Pulmonary Valve Malfunction</condition>
  <arm_group>
    <arm_group_label>pulmonary valve replacement</arm_group_label>
    <description>SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SAPIEN XT</intervention_name>
    <description>Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection</description>
    <arm_group_label>pulmonary valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT
        Transcatheter Heart Valve in the pulmonic position at the time of data collection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical indication and decision for the implantation of an Edwards SAPIEN XT THV made

          -  Data release form

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaus Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Congenital Heart Defects, Heart and Diabetes Center NRW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bramlage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IPPMed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Laval, Ste Foy</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

